X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration will continue to leverage Sentia’s peptide-based platform and Neurocrine’s drug development expertise in CRF biology to discover novel, long-acting corticotropin-releasing factor receptor antagonist peptide therapeutics to address HPA-driven diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Peptide
Partner/Sponsor/Collaborator: Neurocrine Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 16, 2024
Details:
Under the research collaboration, Sentia’s proprietary peptide-based platform will be used to discover novel compounds as corticotropin-releasing factor receptor antagonist for the treatment of hypothalamic-pituitary-adrenal axis modulated diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Peptide
Partner/Sponsor/Collaborator: Neurocrine Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration February 14, 2023
Details:
The collaboration will utilize Sentia’s proprietary peptide-based platform and Neurocrine’s drug development expertise in CRF biology to develop and commercialize medicines with the potential to treat a variety of hypothalamic-pituitary-adrenal (HPA) axis modulated diseases.
Lead Product(s): Astressin B
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Neurocrine Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 27, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
